A 71915;
A 71915 是一种具有高效、竞争性的 natriuretic peptide receptor A (ANP, NPRA) 拮抗剂 (pKi= 9.18). A71915 的剂量依赖性取代 [125I]ANP,Ki为0.65 nM。A71915 (pA2= 9.48) 对大鼠 ANP 诱导的 NB-OK-1 细胞产生 cGMP 的作用。
A 71915 Chemical Structure
CAS No. : 132956-87-7
规格 |
|
是否有货 |
|
100 mg |
; |
询价 |
; |
250 mg |
; |
询价 |
; |
500 mg |
; |
询价 |
; |
* Please select Quantity before adding items.
生物活性 |
A 71915 is a highly potent and competitive natriuretic peptide receptor A (ANP, NPRA) antagonist (pKi= 9.18). A 71915 displaces [125I]ANP dose dependently, with a Ki of 0.65 nM. A71915( pA2= 9.48) against rat ANP-induced cGMP production in NB-OK-1 cells[1].
|
IC50 Target |
A 71915 is a highly potent and competitive natriuretic peptide receptor A (ANP, NPRA) antagonist, with a pKi of 9.18.
|
体外研究 (In Vitro) |
A 71915 combines to Neuroblastoma NB-OK-1 cells, is used in the Cyclic GMP assay. A 71915 shifts the ANP dose-response curve of cyclic GMP production to the right[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
|
体内研究 (In Vivo) |
A 71915 (5 μl; i.m.; 25-30 g male CD-1 mice) affects BNP (1 nmol)- and GRP (0.1 nmol)-induced scratching[2]. A 71915 (30 μg/ kg/ day) inhibits NS-398 on blood pressure decreased[3].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: |
Rat (Male Sprague-Dawley); weighing 150-180 g[3] |
Dosage: |
30 μg/kg/day; infused for 3 weeks |
Administration: |
via a mini-osmotic pump |
Result: |
The inhibitory effect of NS-398 on blood pressure was attenuated by the pretreatment with A 71915 (30 μg/kg/day). |
|
分子量 |
|
Formula |
|
CAS 号 |
|
Sequence |
Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-D-tic-Arg-Cys-NH2 (Disulfide bridge: Cys2-Cys13)
|
Sequence Shortening |
{RC-Cha}-GGRIDRI-{D-Tic-RC}-NH2 (Disulfide bridge: Cys2-Cys13)
|
运输条件 |
Room temperature in continental US; may vary elsewhere.
|
储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
参考文献 |
-
[1]. Delporte C, et al. Discovery of a potent atrial natriuretic peptide antagonist for ANPA receptors in the human neuroblastoma NB-OK-1 cell line. Eur J Pharmacol. 1992;224(2-3):183-188.
[2]. Kiguchi N, et al. Spinal Functions of B-Type Natriuretic Peptide, Gastrin-Releasing Peptide, and Their Cognate Receptors for Regulating Itch in Mice.
[3]. Park BM, et al. Attenuation of renovascular hypertension by cyclooxygenase-2 inhibitor partly through ANP release. Peptides. 2015;69:1-8.
|